Medtronic Launches Resolute Integrity Drug-Eluting Stent In Europe
Superior Deliverability Distinguishes New Medical Device for Coronary Artery Disease
|
|
Medtronic's
Integrity
Stent |
|
August 30, 2010 -- Minneapolis --
Medtronic, Inc. (NYSE: MDT), announced today the CE (Conformité Européene)
mark and international launch of the Resolute Integrity Stent
System for the treatment of coronary artery disease, a leading
cause of death and poor quality of life.
Now available in European
and other countries outside the United States that recognize
the CE mark, the Resolute Integrity Stent System features a novel
drug-eluting coronary stent with superior deliverability – the
ability of the device to traverse the patient’s vasculature and
reach the blockage in the heart artery. |
Based on
the engineering advance of continuous sinusoid technology, the
Resolute Integrity Stent System has been shown in bench testing
and in blinded in vivo physician assessment studies to be significantly more deliverable than the current market-leading alternatives. “Medtronic stents built on continuous sinusoid technology are noticeably more deliverable, giving me greater confidence that I can reach the target lesion, even in patients with especially tortuous anatomy or narrow vessels,” said
Dr. Neal Uren, consultant cardiologist at Lothian University
Hospitals NHS Trust, Royal Infirmary of Edinburgh, and honorary
senior lecturer at the University of Edinburgh, in Scotland. “It’s
a significant innovation for the clinical practice of interventional
cardiology that sets a new gold standard for deliverability.” Coupled
with the MicroTrac delivery system, continuous sinusoid
technology improves deliverability without compromising
other important stent design characteristics like radial
strength. It also improves the stent’s conformability – the
ability of the stent to conform to the natural shape
of the vessel and maintain apposition to the vessel
wall after inflation with the balloon catheter. Medtronic offers a portfolio of bare-metal and drug-eluting stents to address the spectrum of clinical need for patients with coronary artery disease. The Resolute Integrity drug-eluting stent (DES) combines continuous sinusoid technology with two key elements of the original Resolute DES: the cytostatic antiproliferative drug zotarolimus and the highly biocompatible BioLinx polymer. “The Resolute Integrity Stent System provides superior deliverability and powerful performance for complex daily practice,” said Sean Salmon, vice president and general manager of Medtronic’s coronary and peripheral division. “It
offers physicians a compelling new treatment option
for patients with coronary artery disease.” Medtronic is committed to advancing the treatment of cardiovascular disease through collaboration with leading clinicians, researchers and scientists worldwide. About Medtronic
Medtronic, Inc. (www.medtronic.com),
headquartered in Minneapolis, is the global leader in medical technology – alleviating
pain, restoring health and extending life for millions of people
around the world. Any forward-looking
statements are subject to risks and uncertainties such as those
described in Medtronic’s periodic reports on file with
the Securities and Exchange Commission. Actual results may differ
materially from anticipated results.
Source: Medtronic,
Inc.
|